TLDR Taking finasteride can partially improve oxygen levels in hospitalized male patients over 50 with COVID-19 pneumonia, but it doesn't affect other outcomes like death rate or hospital stay length.
The randomized controlled clinical trial conducted by Zarehoseinzade E, Allami A, Ahmadi M, Bijani B, Mohammadi N in 2020 involved 80 hospitalized male patients aged 50 years and above diagnosed with COVID-19 pneumonia. The patients were divided into two groups, with one group receiving routine drug therapy and 5 mg finasteride daily for 7 days. The study found a significant difference in O2 saturation between the two groups on the fifth day (p= 0.018). However, there were no significant differences in mortality rate (2.5% vs 10%; p= 0.166) and length of hospital stay (p= 0.866) between the finasteride and the control group. The conclusion was that a short course of finasteride administration partially improves O2 saturation but does not influence other outcomes in hospitalized male patients aged 50 years and above with COVID-19 pneumonia. Further research with a larger scale and longer follow-up is needed to clarify the role of finasteride in this setting.
49 citations,
January 2021 in “Journal of The European Academy of Dermatology and Venereology” Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
36 citations,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
123 citations,
May 2020 in “Drug Development Research” Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.
5 citations,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
12 citations,
April 2020 in “Medical hypotheses” Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.
47 citations,
April 2020 in “Dermatologic Therapy” Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
32 citations,
July 2016 in “PubMed” 5-alpha reductase inhibitors are generally safe but can cause sexual side effects and require patient education on risks.
January 2023 in “Journal of men's health” Higher dihydrotestosterone may be linked to more inflammation in COVID-19 patients with low testosterone.
Lower LDL-c levels predict higher COVID-19 mortality.
3 citations,
March 2022 in “Annals of Medicine” Hair shedding after COVID-19 is more linked to the disease's severity and inflammation rather than hormones, with women at higher risk.
6 citations,
December 2020 in “Dermatological reviews” COVID-19 may worsen with androgens; anti-androgen drugs could help.
34 citations,
September 2020 in “BMC Endocrine Disorders” Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
